Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: Implications for human acinic cell carcinoma

Cancer Research

Volumn 70, Issue 22, 2010, Pages 9143-9152

  Diegel, Cassandra R ^a   Cho, Kathleen R ^b   El Naggar, Adel K ^c   Williams, Bart O ^a   Lindvall, Charlotta ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; WNT PROTEIN;

ACINAR CELL CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PENETRANCE; PRIORITY JOURNAL; SALIVARY GLAND; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REGRESSION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, ACINAR CELL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; PTEN PHOSPHOHYDROLASE; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN;

EID: 78549289595     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1758     Document Type: Article

References (48)

1. Simental A, Carrau RL. Malignant neoplasms of the salivary glands. In: Cummings CW, editor. Cummings Otolaryngology Head and Neck Surgery. 4th ed.: Elsevier Mosby; 2005, p. 1378-405.
2. Witt RL. Major salivary gland cancer. Surg Oncol Clin N Am 2004;13:113-27.
3. Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol 2008;35:309-19.
4. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988;55:619-25.
5. Lucchini F, Sacco MG, Hu N, et al. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett 1992;64:203-9.
6. Taneja P, Frazier DP, Kendig RD, et al. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 2009;9:423-40.
7. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35-43.
8. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009;122:3589-94.
9. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
10. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008;27 Suppl 2:S43-51.
11. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
12. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
13. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (New York) 1997;275:1943-7.
14. Tamguney T, Stokoe D. New insights into PTEN. J Cell Sci 2007;120:4071-9.
15. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
16. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
18. Motzer RJ, Escu-.01dier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
19. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
20. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006;126:955-68.
21. Δ716 mice. Proc Natl Acad Sci U S A 2008;105:13544-9.
22. Shibata H, Toyama K, Shioya H, et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science (New York) 1997;278:120-3.
23. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001;14:523-34.
24. Brault V, Moore R, Kutsch S, et al. Inactivation of theβ-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 2001;128:1253-64.
25. Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A 2000;97:3444-9.
26. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-55.
27. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78.
28. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999;96:1563-8.
29. Fodde R, Edelmann W, Yang K, et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A 1994;91:8969-73.
30. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A 1995;92:4482-6.
31. Dourdin N, Schade B, Lesurf R, et al. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 2008;68:2122-31.
32. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multifunctional tumor suppressor gene. J Cell Sci 2007;120:3327-35.
33. 2-terminal kinase and inhibition of extracellular signal-regulated kinase. J Pharmacol Exp Ther 334:500-12.
34. Hamada K, Sasaki T, Koni PA, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005;19:2054-65.
35. Sun JF, Phung T, Shiojima I, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A 2005;102:128-33.
36. Li G, Robinson GW, Lesche R, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002;129:4159-70.
37. Batsakis JG, Luna MA, El-Naggar AK. Histopathologic grading of salivary gland neoplasms: II. Acinic cell carcinomas. Ann Otol Rhinol Laryngol 1990;99:929-33.
38. Kim SA, Mathog RH. Acinic cell carcinoma of the parotid gland: a 15-year review limited to a single surgeon at a single institution. Ear Nose Throat J 2005;84:597-602.
39. Dardick I, Burford-Mason AP, Garlick DS, Carney WP. The pathobiology of salivary gland. II. Morphological evaluation of acinic cell carcinomas in the parotid gland of male transgenic (MMTV/v-Ha-ras) mice as a model for human tumours. Virchows Arch A Pathol Anat Histopathol 1992;421:105-13.
40. Diodoro MG, Di Carlo E, Zappacosta R, et al. Salivary carcinoma in HER-2/neu transgenic male mice: an angiogenic switch is not required for tumor onset and progression. Int J Cancer 2000;88:329-35.
41. Carboni JM, Lee AV, Hadsell DL, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005;65:3781-7.
42. Marsh V, Winton DJ, Williams GT, et al. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat Genet 2008;40:1436-44.
43. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-33.
44. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-80.
45. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725-30.
46. Alimonti A, Nardella C, Chen Z, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 120:681-93.
47. Kwon CH, Zhu X, Zhang J, et al. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001;29:404-11.
48. Backman SA, Stambolic V, Suzuki A, et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 2001;29:396-403.